A Preliminary, Open-Label Study of Naltrexone and Bupropion Combination Therapy for Treating Binge Drinking in Human Subjects.
Aims The combination of bupropion and naltrexone has shown efficacy in reducing binge drinking in animal models. This study assessed the tolerability and potential utility of combined naltrexone and bupropion in reducing binge drinking in human subjects. Methods This preliminary study employed an op...
| Publicado en: | Alcohol & Alcoholism Vol. 55; no. 1; pp. 56 - 63 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
Jan2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141628090&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 141628090 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 07350414 FA3 jtl: Alcohol & Alcoholism issn: 07350414 maglogo: N pubinfo: dt: Jan2020 vid: 55 iid: 1 pid: 622 pub: Oxford University Press / USA artinfo: ui: 141628090 141628090 141628090 10.1093/alcalc/agz076 141628090 ppf: 56 ppct: 7 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: A Preliminary, Open-Label Study of Naltrexone and Bupropion Combination Therapy for Treating Binge Drinking in Human Subjects. aug: au: Walter, T Jordan Navarro, Montserrat Thiele, Todd E Pedersen, Cort Kampov-Polevoy, Alexey Garbutt, J C affil: Pharmacology Department, University of North Carolina, 120 Mason Farm Road, 4010 Genetic Medicine Building, Campus Box 7365, Chapel Hill, NC 27514, USA sug: subj: Binge Drinking Drug Therapy Naltrexone Therapeutic Use Bupropion Therapeutic Use Drug Combinations Research Subjects Treatment Outcomes Evaluation Human Single-Blind Studies Clinical Trials Prospective Studies Male Female Research Subject Recruitment Bupropion Administration and Dosage Naltrexone Administration and Dosage Monitoring, Physiologic Insomnia Headache Nausea Diarrhea Male Female ab: Aims The combination of bupropion and naltrexone has shown efficacy in reducing binge drinking in animal models. This study assessed the tolerability and potential utility of combined naltrexone and bupropion in reducing binge drinking in human subjects. Methods This preliminary study employed an open-label, single-arm, 12-week, prospective design. Twelve men and women who exhibited a minimum of five (men) or three (women) binge drinking episodes per month over the past 3 months were recruited. All subjects received both bupropion-extended release 300 mg/day and naltrexone 50 mg/day and were monitored throughout the 3-month treatment period. Binge drinking was assessed using the timeline follow-back method. Results Treatment with combined naltrexone and bupropion reduced the average number of drinks per binge drinking day from 7.8 drinks to 6.4 drinks and reduced the average percentage of binge drinking days per month from 19% (5.7 days/month) to 5% (1.5 days/month). Naltrexone and bupropion were generally well tolerated, with insomnia, headache and nausea/diarrhea being the most common side effects. Six subjects elected to stay on medication after the trial. Conclusions This study suggests that combined naltrexone and bupropion therapy should be further investigated for tolerability and efficacy in reducing binge drinking in humans. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|